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Abstract:  
 
Background  
 
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC) is a 
treatment combining cytoreductive surgery with hyperthermic chemotherapy directly into the 
peritoneal cavity. Recipients may gain extended life when compared with best supportive care; 
yet results often are achieved with substantial morbidity and health-related quality of life 
(HRQOL) deficits. The purpose of this study was to record patient rated outcomes and the 
HRQOL of long-term survivors. 
 
Methods 
 
One hundred and two patients living 12+ months post-treatment completed a survey including 
the Medical Outcomes Study 36-item Short Form Health Survey (SF-36), Functional Assessment 
of Cancer Therapy-Colon (FACT-C), and Pittsburgh Sleep Quality Index. 
 
Results 
 
SF-36 Physical Component scores were significantly lower than general population norms (46.7, 
z = −2.943, P = 0.003), while Mental Component scores were significantly higher (53.6, 
z = 4.208, P ≤ 0.001). FACT scores were higher than general FACT normative scores. The 
majority (56%) of these survivors reported significant sleep quality impairment. 
 
Conclusion  
 
Although most HRQOL scores were comparable to or higher than those of the general 
population, long-term physical and functional deficits remain. These deficits, along with the poor 
sleep quality of recipients, may be improved by survivorship programs or targeted psychosocial 
interventions. J. Surg. Oncol. 2012; 106:376–380. © 2012 Wiley Periodicals, Inc. 
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Article: 
 
Introduction 
 
Peritoneal dissemination of intra-abdominal malignancy is a uniformly fatal condition. Despite 
advances in systemic chemotherapy, long-term survival without surgery is essentially unknown 
in this setting. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy 
(CS + HIPEC) has allowed for long-term survival in a subset of patients undergoing the 
procedure. CS + HIPEC combines cytoreductive surgery with chemoperfusion directly into the 
peritoneal cavity 1. CS + HIPEC offers individuals with peritoneal disease the possibility of 
achieving extended survival, although it can be associated with substantial morbidity (e.g., 27–
56%) 1, 2. Quality of life (QOL) research has revealed additional post-operative complications, 
including anxiety, sleep disturbance, and depressive symptoms 3–5. Despite a 20-year history, 
there are few methodologically sound health-related QOL (HRQOL) and symptom management 
studies in the CS + HIPEC literature 6. 
 
There are three important reasons to collect HRQOL and symptom data in the HIPEC context. 
First, post-treatment functioning data can inform expectations and pre-treatment decision-
making. Despite detailed efforts to educate patients, most do not, perhaps cannot, fully 
comprehend the potential impact of CS + HIPEC on all aspects of functioning. Next, routine 
systematic monitoring could improve patient care. After hospital discharge, patients may be 
geographically distant and have only one follow-up appointment with their HIPEC surgeon. 
Likewise, patients may report symptoms only when asked about them directly, posing a risk that 
certain symptoms will go undetected without systematic data collection6. Finally, systematic 
monitoring of symptoms and HRQOL can assist with survivorship planning 7. 
 
HRQOL and troubling symptoms, including sleep disturbances, are under-investigated in 
CS + HIPEC survivors. Sleep concerns in the context of cancer may be related to predisposing 
(e.g., psychological disorder), novel (e.g., pain), or maintaining (e.g., drugs) factors 8. In 
addition to its association with HRQOL, sleep quality has been associated with numerous health 
problems, including immunosuppression and cardiovascular disease 8, 9. In one of the few 
studies examining the HRQOL of long-term CS + HIPEC survivors (i.e., ≥3 years), poor sleep 
was one of the top three psychosocial concerns 3, and approximately 35% of participants 
indicated current or past concerns with sleep. Utilization of a brief, psychometrically sound 
instrument can clarify the prevalence and nature of sleep disturbances. 
 
The purpose of this study was to collect HRQOL, sleep quality, and symptom data from long-
term CS + HIPEC survivors. We hypothesized that the majority of survivors would report 
HRQOL deficits relative to that of the general population as well as significant physical 
symptoms and sleep quality impairment. 
 
Materials and Methods 
 
This is a cross-sectional, descriptive study designed to gather information about long-term 
survivors of CS + HIPEC. Participants were selected from a prospectively maintained 
comprehensive database of recipients at Wake Forest Baptist Health (WFBH). Eligibility criteria 
included: (1) recipient of CS + HIPEC 12 or more months prior to study initiation; (2) updated 
contact information; and (3) English literate. This study was approved by the WFBH Institutional 
Review Board. 
A telephone script was used to make recruitment phone calls. Investigators explained the purpose 
of the study and obtained preliminary verbal consent. Subsequently, a cover letter, written 
consent, and instruments were mailed. Phone calls were made if instruments were incomplete or 
missing. Gas cards ($25) and signed consent forms were mailed to participants. 
The Medical Outcomes Study 36 Short-Form Health Survey 
The Short Form Health Survey (SF-36) is a 36 item, generic health measure that assesses 
perceived health in eight areas: physical functioning (PF), role-physical (RP), role-emotional 
(RE), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), and mental 
health (MH) 10–12. The Mental Component Summary (MCS) and Physical Component 
Summary (PCS) are the comprehensive components derived from the eight scales. Higher scores 
indicate better functioning. High scores on the MCS indicate minimal psychological distress and 
functional limitations due to emotional problems. High scores on the PCS denote minimal 
physical or role limitations and good GH. The results from the general U.S. population census 
were utilized as norm anchors, permitting ease of comparison between clinical and general 
populations. 
 
The Functional Assessment of Cancer Therapy-Colon (FACT-C) Scale 
 
The Functional Assessment of Cancer Therapy-General (FACT-G) is a 27-item self-report 
questionnaire that measures QOL 13. The FACT-C is the FACT-G plus the 9-item colon 
subscale, selected because its items best address symptoms associated with Disseminated 
Peritoneal Carcinomatosis (DPC). The FACT consists of four subscales measuring physical 
(PWB), functional (FWB), social/familial (SFWB), and emotional well-being (EWB), and 
provides a total QOL score as well. Patients rate how they feel over the past 7 days on a 5-point 
Likert-type scale. Higher scores indicate better QOL. FACT scores were compared to published 
norms for cancer survivors. A Trial Outcome Index (TOI) representing PWB + FWB + C 
subscale was used to assess treatment impact on PF. Cronbach's alpha is: PWB (0.82), FWB 
(0.80), SFWB (0.69), EWB (0.74), FACT-G (0.89) 13. 
Pittsburg Sleep Quality Index 
 
The Pittsburgh Sleep Quality Index (PSQI) assesses sleep quality and disturbances over the past 
4 weeks 14. Nineteen of the 24 items are client-rated and used in score tabulation. The scorer 
assigns an ordinal score, ultimately deriving a global score and seven component scores (sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping 
medication, and daytime dysfunction). Component scores (i.e., 0–3) are given equal weight, 
indicating a possible global score of 0–21. Lower scores reflect better sleep quality. A 
component score of “0” indicates no difficulty; “3” reflects severe difficulties. A global cut-off 
score of 5 was established to denote clinically significant sleep impairment 15. A score above 
this cut-off suggests severe problems in a minimum of two areas or moderate-intensity problems 
in three or more. Scores, therefore, inherently reflect both the number and severity of sleep–wake 
disturbances 14. 
 
Data Analysis 
 
Descriptive statistics, including means and standard deviations for continuous measures and 
frequencies and proportions for categorical data, were calculated for all measures. Differences 
between participants and eligible non-participants were compared on: age, gender, resection 
status, primary tumor site, and performance status. Norm-based scores (NBS) and their 
associated z-statistics were calculated with general population parameters for the SF-36 data 
(Table II). Scores that differed significantly from 50 (the general population mean for NBS) with 
a P-value <0.05 are considered significantly different from general population means. 
Additionally, the sleep quality of participants was examined. Relationships between sleep quality 
and HRQOL were examined with Pearson's product moment correlations. Those relationships 
strong enough to be considered at least moderate in intensity (r ≥ 0.50) are reported. Finally, the 
contributions of two independent, categorical surgical variables (i.e., resection status and primary 
tumor site) to HRQOL PCS and MCS were examined in an analysis of covariance (ANCOVA); 
this ANCOVA also adjusted for age at the time of surgery and length of time since surgery. The 
respective groups were combined into resection status groups of R0/R1, R2a, and R2b/c (R2c 
status had only one subject), while primary tumor sites were grouped into appendix, colon, and 
“other”. To determine which groups varied significantly, pair-wise comparisons of mean PCS 
levels by primary disease and resection status were performed if the overall effect was found to 
be significant. The Kaplan–Meier method was used to estimate survival for the entire 
CS + HIPEC cohort; estimates are displayed graphically (Fig. 1). 
 
 
 
 
 
Results 
 
A total of 649 patients were at least 1-year status post-CS + HIPEC. Of those, 224 (35%) were 
alive, 425 (65%) deceased. Of the 224 eligible, 2 died mid-study; 35 had inaccurate telephone 
numbers. Of the remaining 187, 136 individuals consented verbally, while the remaining 51 
prospective participants were not reached or declined. A total of 102 survivors returned 
completed questionnaires (refer to Table I for sociodemographic characteristics). Age was the 
only variable tested that differed significantly between participants and non-participants, with 
non-responders (mean age at CS + HIPEC = 50.1) averaging approximately 5 years younger than 
responders (54.7; P = 0.005). When data from the entire sample of CS + HIPEC recipients were 
examined, approximately 50% were alive 2 years post-treatment (Fig. 1). A Kaplan–Meier 
survival curve (Fig. 1) provides context for the performance of these long-term survivors relative 
to all peers who received CS + HIPEC at least 12 months prior to the study (N = 649; 
CS + HIPEC date range= 12/1991–1/2009). When all 649 recipients are included, the median 
(midpoint) survival is 2.3 years. Estimates of survival for all recipients (Fig. 1) are: year 1: 
69.1% (SE = 1.8%), 2: 52.2% (2.0%), 3: 43.1% (2.0%), 5: 31.0% (2.0%), 10: 18.6% (2.1%). As a 
basis of comparison, the mean years since surgery for the long-term survivors included in this 
study is 4.2 (range = 1.1–16.5). 
 
 
 
HRQOL and Daily Activities 
 
Complete SF-36 results are reported in Table II. The PF [NBS = 46.0, z = −3.676, P ≤ 0.001], RP 
(NBS = 46.6, z = −2.844, P = 0.004), and PCS (NBS = 46.7, z = −2.943, P = 0.003) scores were 
significantly lower than those of the general population, while the MH (NBS = 53.6, 
z = 4.002, P < 0.001), BP (NBS = 52.2, z = 2.084, P = 0.037), and the MCS (NBS = 53.6, 
z = 4.208, P ≤ 0.001) were significantly higher. Table III includes patient-rated limitations on 
daily activities. A significant percentage (i.e., >15%) of patients indicated that they were “limited 
a lot” in four areas, including their ability to: climb several flights of stairs (16%), walk several 
blocks (18%), walk >1 mile (26%), and in vigorous activities (43%). 
 
 
 
Resection Status HRQOL 
 
The contributions of resection status and primary tumor site to PCS and MCS were examined. 
Although resection status did not produce significant main effects in the model, primary tumor 
site showed a significant main effect on the PCS of participants (F(2, 95) = 3.16, P = 0.047). To 
determine the origin of this effect, pair-wise comparisons of mean PCS levels by primary disease 
were performed. Those with a primary tumor site of appendix (estimated mean = 46.5) versus 
“other” (39.5) demonstrated significant differences (better) in PF (P = 0.014). 
 
Self-Report of Specific Symptoms 
 
In an open-ended format, patients were asked to identify and rate their most troubling current 
symptoms [i.e., 1 (very mild) to 10 (as severe as you could imagine)]. Investigators categorized 
symptom clusters. Patients reported a total of 156 symptoms, averaging 1.5 symptoms reported 
per patient. A total of 17 participants wrote “none,” while 13 left the question blank. The most 
common unifying symptom constellation was related to GI distress (e.g., bloating, diarrhea). 
Symptoms from this category were identified 56 times by responders with an average intensity 
rating of 5.8. 
Similarly, on the FACT-C, a significant percentage (i.e., >15%) of patients indicated that they 
have problems with diarrhea (18%). On the global QOL question on the FACT, 74% reported 
“quite a bit” or “very much” to the question “I am satisfied with the quality of my life right 
now.” 
Sleep Quality 
On the PSQI, a total of 56% (N = 57) of participants scored above the clinical cut-off score of 5, 
indicating a high presence of significant sleep disturbances. The mean PSQI score was 6.8 
(SD = 4.4, range = 0.0–19.6). The highest scale score mean was on the Sleep Disturbances Scale 
(m = 1.5), the lowest on Daytime Dysfunction (m = 0.7). 
Relationships between sleep quality and HRQOL were examined. Positive relationships (better 
sleep was associated with higher QOL) were noted between global sleep quality scores and RP 
(r = 0.54), GH (r = 0.51), VT (r = 0.57), and PCS (r = 0.51), P < 0.0001 for all comparisons. 
Moderate correlations also were noted between Sleep Disturbance and BP (r = 0.54), P < 0.0001. 
 
Discussion 
Our hypotheses that long-term survivors report HRQOL deficits relative to the general 
population as well as significant physical symptoms and sleep impairment proved accurate, 
within the context of four major findings. 
First, a number of physical symptoms remain yet patients are adapting. The PF subscale scores 
on the SF-36 fell significantly below the general population norms, while the MH and MCS were 
significantly higher than norms. Together, these results suggest that long-term survivors may 
achieve acceptable emotional well-being 1 or more years post-treatment while physical and 
functional deficits remain. 
All of these participants share the fact that they were presented with the stark possibility of 
limited lifespan and few treatment options. CS + HIPEC is a serious, perhaps traumatic event for 
many, if not all, patients. Although not measured directly or over time within this cohort, it is 
possible that this confrontation with mortality was shocking and produced a type of post-
traumatic growth (PTG). PTG has been described as the gradual internal paradigm shifts that 
may occur following internal disruption spurred by trauma 15, 16. Enhancement of self regard 
and life philosophy are only a few areas that may be susceptible to gradual growth after trauma. 
The concept of response shift, suggesting that people will accommodate to new norms and 
experience shifts in internal standards, also may help to explain these seemingly contradictory 
findings of decrements in physical well being accompanied by improved MH 17, 18. Compared 
to their immediate pre- and post-treatment QOL, these survivors may perceive their current 
mental health as relatively high. 
When compared to FACT normative data from a general adult sample [i.e., PWB 22.7 (5.4), 
SWB 19.1 (6.8), EWB 19.9 (4.8), FWB 18.5 (6.8), and FACT-G 80.1 (18.1)], the scores for 
CS + HIPEC recipients are higher and suggest comparatively good overall QOL 19. However, 
the PCS on the SF-36 indicate that recipients score low relative to the norm in the general 
population. Differences between QOL instruments may explain discrepancies. The SF-36 
includes additional questions on activities of daily living, whereas the FACT is measuring more 
global aspects of HRQOL. It is only in the Colon subscale of the FACT, a measure of specific 
symptoms, where we see the QOL deficits and specific symptom clusters more clearly. 
Similarly, even though a significant percentage of people rated their health as excellent 
(Table III), 43% reported being “limited a lot” with vigorous activities. In conclusion, reports of 
lasting physical decrements and symptoms alongside concurrent reports of high HRQOL may 
reflect a response shift and process of adaptation over the course of many months and years. 
Specific symptoms reported both formally and informally have implications for ongoing 
symptom management efforts. 
Second, the mean sleep quality score of 6.8 was above the clinical cut-off score that marks the 
presence of significant sleep quality impairment14. A total of 56% of participants endorsed 
clinically impaired sleep quality, compared to a normal population estimate (e.g., 26%) of sleep 
impairment 20. Significant positive relationships between global sleep quality scores and 
HRQOL subscales suggest the interrelated nature of sleep and alternate domains of functioning. 
Interestingly, when presented with the opportunity to self-identify troubling symptoms, few 
identified sleep disturbance specifically. This underscores the importance of presenting people 
with symptom checklists or inquiring directly about symptoms in order to achieve accurate 
diagnoses and corresponding treatment plans to treat impaired sleep aggressively. Targeted sleep 
interventions could help improve physical and MH outcomes as well. 
Third, resection status breakdown included 65% = R0/R1, 27% = R2a, 10% = R2b, 1% = R2c. 
This finding is similar to previous work that suggested resection status was correlated 
significantly with improved survival status and that patients who underwent a complete resection 
(i.e., R0/R1) had better outcomes than their incompletely resected counterparts, regardless of 
primary diagnosis 1. Relative to long-term HRQOL, however, resection status did not seem to 
produce significant effects on component scores. Tuttle et al. 21 reported similarly that resection 
status was not a significant contributor to HRQOL. In conclusion, those with a more desirable 
resection status may have improved survival estimates but do not demonstrate improved overall 
physical and mental HRQOL long-term 1. 
Fourth, unlike resection status, primary tumor site did demonstrate a significant main effect on 
the PCS of survivors, with individuals with a primary diagnosis of appendiceal cancer (N = 65% 
of sample) reporting higher PF. Already supported in the literature, Levine et al. 1 noted the 
differential clinical outcomes experienced by patients based on the pathological characteristics of 
their primary diagnosis and concluded that primary tumor site is correlated with improved 
survival. 
Several study limitations exist. First, participants were patients of one hospital and four surgeons. 
Only those with accurate contact information and with adequate health completed the survey. 
Those who lived less than 12 months post-surgery or who were too ill to complete the 
instruments are not represented. Second, ethnic and racial statistics highlight the sample's 
homogeneity. Intense recruitment efforts were extended to all patients, however, suggesting that 
this sample adequately represents long-term survivors. Third, although participants ranged from 
1.1 to 16.5 years post-CS + HIPEC, data were collected at one time point along their recovery 
trajectories. Factors unrelated to CS + HIPEC (e.g., aging, alternative treatments, recurrence) 
may have impacted responses. Previous CS + HIPEC researchers have demonstrated significant 
changes in HRQOL scores across recovery, with lowest scores reported immediately post-
procedure 22. To clarify the role of other variables, comparisons were made to population norms, 
and time-since-surgery differences were assessed. Yet it remains important to acknowledge the 
possible contributions of other influential variables, such as additional health problems not 
identified in this study. The inclusion of a non-CS + HIPEC comparison group in future studies 
could provide greater clarity as to the extent to which QOL, sleep, and reported symptoms are 
due to CS + HIPEC. 
In summary, we believe that this study represents the largest survey of long-term survivors post-
CS + HIPEC to date. Recipients living 1 or more years post-treatment report physical and 
functional HRQOL limitations, including sleep impairment. The opportunity to self-identify 
troubling symptoms revealed that GI distress is a prominent area for symptom management. 
Overall MH functioning was improved relative to that expected in the general population. These 
findings suggest, paradoxically, that long-term survivors may experience both distress and 
emotional growth. These survivors identified specific areas of concern that could improve with 
attention from the healthcare team. Ongoing monitoring of symptoms (including GI distress), 
sleep quality and HRQOL over the months following treatment can improve patient functioning 
and assure that increased survival is not achieved at the expense of a life of quality. 
The next steps for psychosocial researchers include the design of methodologies that include 
control groups. Such findings permit an enhanced ability to delineate the extent to which 
reported symptoms are due to CS + HIPEC and have direct implications for the establishment of 
patient education efforts, monitoring, psychosocial interventions, and follow-up care. 
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